Ocular Therapeutix CMO sells 3,510 shares for taxes

Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open‑market sale of 3,510 shares of common stock at a weighted average price of $7.74 per share on February 20, 2026.

Rhea-AI Filing Summary

Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open‑market sale of 3,510 shares of common stock at a weighted average price of $7.74 per share on February 20, 2026. The sale was executed under a durable automatic sale instruction adopted on June 1, 2024 to cover tax withholding from restricted stock units that vested on February 11, 2026, and is described as non‑discretionary. Following this transaction, Waheed beneficially owns 314,907 shares of Ocular Therapeutix common stock.

Insider Trade Summary

Net Seller: 3,510 shares

Net Sell 1 txn

Insider Waheed Nadia

Role Chief Medical Officer

Sold 3,510 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,510	$7.74	$27K

Holdings After Transaction: Common Stock — 314,907 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on June 1, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.6838 to $7.7900, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

FAQ

What insider transaction did Ocular Therapeutix (OCUL) report for Nadia Waheed?

Ocular Therapeutix reported that Chief Medical Officer Nadia Waheed sold 3,510 shares of common stock at a weighted average price of $7.74. The transaction was executed as an automatic sell-to-cover trade to satisfy tax withholding obligations tied to vested restricted stock units.

Was the OCUL insider stock sale by Nadia Waheed a discretionary trade?

The sale was not discretionary. It occurred under a durable automatic sale instruction adopted on June 1, 2024, specifically to cover tax withholding on restricted stock units that vested on February 11, 2026, rather than reflecting an independent investment decision by the insider.

How many Ocular Therapeutix (OCUL) shares does Nadia Waheed own after the Form 4 transaction?

After selling 3,510 shares to cover tax obligations, Chief Medical Officer Nadia Waheed beneficially owns 314,907 shares of Ocular Therapeutix common stock. This remaining stake reflects her continuing equity interest in the company following the reported February 20, 2026, transaction.

What price range applied to the OCUL insider sale reported by Nadia Waheed?

The weighted average sale price was $7.74 per share, with individual trades executed between $7.6838 and $7.79. The shares were sold in multiple transactions within this range, and detailed trade breakdowns are available upon request from the company or regulatory staff.

Why did Ocular Therapeutix (OCUL) file this Form 4 for Nadia Waheed?

The Form 4 discloses an insider sale of 3,510 common shares by Chief Medical Officer Nadia Waheed. The sale was made under an automatic instruction to satisfy tax withholding obligations related to restricted stock units that vested on February 11, 2026, as required by securities regulations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 06:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waheed Nadia

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		S(1)		3,510(1)	D	$7.74(2)	314,907	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on June 1, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.6838 to $7.7900, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Todd Anderman, Attorney-in-Fact for Nadia Waheed	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.